作者
Foong See Mei,Shirley Lau Sim Ee,Suresh Kumar Subbiah,Muthusamy Thangavel,Muralidharan Anbalagan,Sasikala Chinnappan,Ravishankar Ram Mani
摘要
Background Influenza A viruses are responsible for seasonal epidemics that pose a threat to human health and mortality rates all over the world. For a number of years, oseltamivir was a significant step forward in the treatment of influenza virus. As a result of the evolution of resistant strains of influenza A, the therapeutic utility of the virus is decreasing, which highlights the necessity of developing new treatment approaches. Objective This review aims to address a comprehensive summary of the growing problems associated with oseltamivir resistance and evaluates recent studies targeting phytochemicals with unique mechanisms that could bypass existing strategies of influenza A virus resistance. Methods A systematic literature survey from multiple entities such as PubMed, MDPI, Science Direct, Google Scholar, Scopus and Research Gate was performed and special emphasis into virtual screening platforms of phytochemical compounds against influenza A was conducted. Results The study identified key compound classes include alkaloids (e.g., harmaline, colchicine), flavonoids (e.g., quercetin, naringenin derivatives), sterols (e.g., β-sitosterol), and terpenoids (e.g., santonin, essential oil constituents). Reported mechanisms are multi-modal: hemagglutinin and neuraminidase binding/inhibition, M2 channel interference, polymerase interactions, virucidal envelope disruption, and host-directed immunomodulation. Conclusion The necessity for novel anti-influenza therapeutics is driven by the emergence of oseltamivir-resistant influenza A virus strains. Phytochemicals, specifically the identified classes (alkaloids, flavonoids, sterols, and terpenoids), represent a promising pharmacological reservoir. Their demonstrated capacity for multi-modal targeting of diverse viral and host functions offers a viable strategy to circumvent established resistance mechanisms, thereby guiding the development of robust next-generation anti-influenza treatments.